NO20050067L - Pegylert T1249 polypeptid - Google Patents

Pegylert T1249 polypeptid

Info

Publication number
NO20050067L
NO20050067L NO20050067A NO20050067A NO20050067L NO 20050067 L NO20050067 L NO 20050067L NO 20050067 A NO20050067 A NO 20050067A NO 20050067 A NO20050067 A NO 20050067A NO 20050067 L NO20050067 L NO 20050067L
Authority
NO
Norway
Prior art keywords
pegylated
polypeptide
polypeptide compounds
admixture
preparing
Prior art date
Application number
NO20050067A
Other languages
English (en)
Inventor
Pascal Sebastian Bailon
Chee-Youb Won
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20050067L publication Critical patent/NO20050067L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

SAMMENDRAG Pegylerte Tl 249- polypeptid-forbindelser er beskrevet. Det beskrives også farmasøytiske preparater inneholdende pegylerte Tl 249-polypeptid-forbindelser i blanding med et farmasøytisk akseptabelt tilsettingsmiddel for hemming av HIV-infeksjon, og fremgangsmåter for fremstilling av preparatene.
NO20050067A 2002-07-24 2005-01-06 Pegylert T1249 polypeptid NO20050067L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39819002P 2002-07-24 2002-07-24
US43921303P 2003-01-10 2003-01-10
PCT/EP2003/007711 WO2004013165A1 (en) 2002-07-24 2003-07-16 Pegylated t1249 polypeptide

Publications (1)

Publication Number Publication Date
NO20050067L true NO20050067L (no) 2005-04-22

Family

ID=31498587

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050067A NO20050067L (no) 2002-07-24 2005-01-06 Pegylert T1249 polypeptid

Country Status (21)

Country Link
US (1) US7084261B2 (no)
EP (1) EP1546193A1 (no)
JP (1) JP4381302B2 (no)
KR (1) KR100630176B1 (no)
CN (1) CN100352837C (no)
AR (1) AR040650A1 (no)
AU (1) AU2003250079B2 (no)
BR (1) BR0312841A (no)
CA (1) CA2492954C (no)
HR (1) HRP20050025A2 (no)
IL (1) IL166037A0 (no)
MX (1) MXPA05000798A (no)
NO (1) NO20050067L (no)
NZ (1) NZ537493A (no)
PA (1) PA8577801A1 (no)
PE (1) PE20040679A1 (no)
PL (1) PL375308A1 (no)
RU (1) RU2294938C2 (no)
TW (1) TW200427697A (no)
UY (1) UY27900A1 (no)
WO (1) WO2004013165A1 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004308952A1 (en) * 2003-12-23 2005-07-14 Centocor, Inc. Anti-retroviral agents, compositions, methods and uses
EP1720899A2 (en) * 2004-02-23 2006-11-15 Borean Pharma A/S Multimerised hiv fusion inhibitors
MXPA06010505A (es) * 2004-03-15 2006-12-19 Nektar Therapeutics Al Corp Composiciones y conjugados, basados en polimeros, de inhibidores de ingreso de vih.
CN100475270C (zh) * 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
CH690143A5 (de) * 1995-01-27 2000-05-15 Rieter Automotive Int Ag Lambda/4-Schallabsorber.
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US6281331B1 (en) * 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
PE20010288A1 (es) * 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
US6469136B1 (en) * 1999-07-07 2002-10-22 Trimeris, Inc. Methods and composition for peptide synthesis

Also Published As

Publication number Publication date
JP2006515272A (ja) 2006-05-25
UY27900A1 (es) 2003-12-31
AU2003250079B2 (en) 2006-07-27
AU2003250079A1 (en) 2004-02-23
HRP20050025A2 (en) 2006-02-28
MXPA05000798A (es) 2005-04-19
RU2005105578A (ru) 2005-10-27
CA2492954A1 (en) 2004-02-12
CN100352837C (zh) 2007-12-05
KR100630176B1 (ko) 2006-10-02
EP1546193A1 (en) 2005-06-29
WO2004013165A1 (en) 2004-02-12
BR0312841A (pt) 2005-12-06
AR040650A1 (es) 2005-04-13
TW200427697A (en) 2004-12-16
PL375308A1 (en) 2005-11-28
CA2492954C (en) 2009-12-22
JP4381302B2 (ja) 2009-12-09
IL166037A0 (en) 2006-01-15
CN1671735A (zh) 2005-09-21
PE20040679A1 (es) 2004-10-06
US20040171542A1 (en) 2004-09-02
KR20050027255A (ko) 2005-03-18
RU2294938C2 (ru) 2007-03-10
US7084261B2 (en) 2006-08-01
PA8577801A1 (es) 2004-05-26
NZ537493A (en) 2007-05-31

Similar Documents

Publication Publication Date Title
DK0951474T3 (da) Nye cyclosporinderivater, deres fremstilling og farmaceutiske præparater deraf
NO20050066L (no) Pegylert T20 polypeptid
NO2013017I2 (no) (a)dekstrometorfan eller et farmasøytisk akseptabelt salt derav, for eksempel dekstrometorfanhydrobromid og (b) quinidin eller etfarmasøytisk akseptabelt salt derav, for eksempel quinidinsulfat
DK0398558T3 (da) Isolering og strukturbestemmelse af det cytostatiske, lineære depsipeptid dolastin 15
MXPA04003532A (es) Pirimidinonas como receptor 1 de la hormona concentradora de melanina.
NO305657B1 (no) 4-substituerte piperidinderivater og farmas°ytisk preparat derav
DK1163349T3 (da) Medicinske præparater til behandling af alfa-galactosidase A-mangel
RS20090086A (en) Nucleoside analogs with carobxamidine modified monocyclic base
TR200002299T2 (tr) Epotilon kompozisyonları.
NO952132L (no) Farmakologiske aktive pyridin-derivater og deres fremstilling
ATE290015T1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zubereitungen
GEP20063799B (en) Tropane derivatives useful in therapy
FI940807A0 (fi) Peptidejä, joilla on kasvuhormonia vapauttavaa aktiivisuutta
ATE380822T1 (de) Funf-helix protein
MY125516A (en) Novel composition based on thiazolidinedione and metformin and use
TR200103460T2 (tr) 5-Fenil-pirimidin türevleri
CY1105235T1 (el) Συνθεσεις λασοφοξιφενης
DK0611572T3 (da) Fremgangsmåde til fremstilling af et frysetørret cetrorelix præparat
DE602004014163D1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
DK0539479T3 (da) Heterocykliske forbindelser
DE69636285D1 (de) ISOLIERTES FrpB NUKLEINSÄUREMOLEKÜL UND ENTSPRECHENDE IMPFSTOFF
NO20050067L (no) Pegylert T1249 polypeptid
DK1379508T3 (da) N-(aryl)-2arylethensulfonamider og terapeutiske anvendelser deraf
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
DK1549329T3 (da) Ekstrakt med antitumoraktivitet og anti-giftaktivitet

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application